HUTCHMED (China) Limited (HCM) RNS Announcements

Add to Alert list
Date Time Source Announcement
28 Nov 2025 08:30 AM
RNS
Total Voting Rights
27 Nov 2025 07:00 AM
RNS
HUTCHMED Highlights Data at ESMO and ASH
05 Nov 2025 07:00 AM
RNS
Enrollment Complete in SAFFRON Global Phase III
03 Nov 2025 07:00 AM
RNS
Updates from R&D Event
23 Oct 2025 07:00 AM
RNS
HUTCHMED Presents Data at AACR NCI EORTC
21 Oct 2025 09:30 AM
RNS
Vesting of awards under Long Term Incentive Plan
14 Oct 2025 09:30 AM
RNS
Appointment of Independent Non-executive Director
13 Oct 2025 07:05 AM
RNS
Data to be Presented at the 2025 ESMO Congress
02 Oct 2025 07:00 AM
RNS
HUTCHMED Highlights Data to be Presented at ESMO
30 Sep 2025 09:30 AM
RNS
Total Voting Rights
12 Sep 2025 07:00 AM
RNS
HUTCHMED to Present R&D Updates on October 31 2025
05 Sep 2025 07:00 AM
RNS
HUTCHMED Highlights Data to be Presented at CSCO
26 Aug 2025 07:00 AM
RNS
Directorate Change
20 Aug 2025 07:00 AM
RNS
HUTCHMED Completes Enrollment of Phase III Trial
07 Aug 2025 12:00 PM
RNS
2025 Interim Results
03 Jul 2025 09:30 AM
RNS
HUTCHMED to Announce 2025 Half-Year Results
02 Jul 2025 10:00 AM
RNS
Update on Joint Corporate Brokers in London
30 Jun 2025 09:30 AM
RNS
Total Voting Rights
30 Jun 2025 09:30 AM
RNS
China Approval based on Phase III SACHI Trial
30 Jun 2025 09:30 AM
RNS
Blocklisting Six Monthly Return
10 Jun 2025 11:00 AM
RNS
Grant of Share Options and Awards under LTIP
05 Jun 2025 07:00 AM
RNS
HUTCHMED and Innovent Announce NDA Acceptance
02 Jun 2025 07:00 AM
RNS
HUTCHMED Highlights SACHI Phase III Data at ASCO
30 May 2025 09:30 AM
RNS
Total Voting Rights
23 May 2025 07:00 AM
RNS
HUTCHMED Highlights Data to be Presented at ASCO
13 May 2025 11:45 AM
RNS
AGM held on May 13, 2025 – Poll Results
24 Apr 2025 07:00 AM
RNS
HUTCHMED - Data to be Presented at AACR 2025
22 Apr 2025 07:00 AM
RNS
HUTCHMED Completes Enrollment of Phase II Study
07 Apr 2025 09:30 AM
RNS
2024 Annual Report and Notice of AGM
31 Mar 2025 10:30 AM
RNS
Extraordinary General Meeting – Poll Results
21 Mar 2025 10:00 AM
RNS
NMPA Conditional Approval for TAZVERIK®
20 Mar 2025 09:30 AM
RNS
Retirement of Independent Non-executive Directors
20 Mar 2025 07:00 AM
RNS
HUTCHMED Highlights Savolitinib SAVANNAH Phase II
19 Mar 2025 01:45 PM
RNS
Publication of Form 20-F
19 Mar 2025 11:00 AM
RNS
2024 Final Results and Business Updates
19 Mar 2025 07:00 AM
RNS
Phase II/III Study of Fruquintinib and Sintilimab
14 Mar 2025 09:30 AM
RNS
Adoption of the 2025 Long Term Incentive Plan
14 Mar 2025 09:30 AM
RNS
Vesting of awards under Long Term Incentive Plan
13 Mar 2025 09:30 AM
RNS
Notice of Extraordinary General Meeting
06 Mar 2025 10:00 AM
RNS
Completed Enrollment of Phase II Study
05 Mar 2025 10:00 AM
RNS
Directorate Change
03 Mar 2025 07:00 AM
RNS
Overseas Regulatory Announcement
28 Feb 2025 03:00 PM
RNS
Overseas Regulatory Announcement
19 Feb 2025 08:30 AM
RNS
Notice of Results
28 Jan 2025 09:00 AM
RNS
Overseas Regulatory Announcement
14 Jan 2025 07:00 AM
RNS
Full Approval for ORPATHYS in China
02 Jan 2025 07:01 AM
RNS
China NDA Acceptance for ORPATHYS and TAGRISSO
02 Jan 2025 07:00 AM
RNS
Overseas Regulatory Announcement
02 Jan 2025 07:00 AM
RNS
US$608m Divestment of Non-Core Joint Venture
31 Dec 2024 08:30 AM
RNS
Appointment of Joint Corporate Broker

Hutchmed China  Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) is headquartered in Hong Kong and markets its products worldwide.

It was founded in 2000 and listed in London in 2018 under the ticker HCM. 

UK 100

Latest directors dealings